Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Capital Expenditures (2022 - 2025)

Gossamer Bio (GOSS) has 2 years of Capital Expenditures data on record, last reported at $53000.0 in Q2 2025.

  • For Q2 2025, Capital Expenditures changed N/A year-over-year to $53000.0; the TTM value through Sep 2025 reached $79000.0, changed N/A, while the annual FY2022 figure was $410000.0, 73.48% down from the prior year.
  • Capital Expenditures reached $53000.0 in Q2 2025 per GOSS's latest filing, up from $26000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $361000.0 in Q4 2022 and bottomed at -$228000.0 in Q3 2022.